Digital Digest Unveils AI Insights Hub for Australian Businesses
SUNSHINE COAST, QUEENSLAND, AUSTRALIA / ACCESS Newswire / June 6, 2025 / Digital Digest, Australia's leading online publication for digital marketing insights, today announced the launch of its new AI Insights Hub. This is a dedicated resource designed to empower Australian businesses and professionals with expert, human-first guidance to navigate through the extensive range of AI tools becoming readily available to the market.
The introduction of this comprehensive 'Australian Tailored' hub comes at a pivotal moment, as AI continues to fundamentally reshape every aspect digital marketing and how businesses alike can leverage AI platforms within business in Australia.
Recent advancements, including Google's expanded AI Overviews and the integration of AI-powered tools across major platforms like Snapchat and YouTube, underscore the urgent need for clear, actionable intelligence and better understanding for business owners and professionals.
The AI Hub will feature a collection of resources, including in-depth research reports on AI comparisions, trends specific to Australia, practical guides and case studies on how to best utilised AI across different industries. Along with this, upcoming exclusive interviews some of Australia's leading digital marketing professionals utilising AI and will provide exclusive insights into their tips and tricks for the best possible outcome.
'AI and Digital Marketing is undergoing an unprecedented transformation in 2025 and the majority driven by AI, and Australian businesses need a trusted partner to navigate these changes effectively,' stated Benjamin Paine, Founder at Digital Digest & Managing Director at Digital Nomads HQ. 'Our new AI Hub is a testament to our commitment to providing experienced insight and that we are dedicated to empowering marketers and business owners with the knowledge and tools necessary to leverage AI's immense potential.'
The strategic importance of AI in digital marketing is further highlighted by its ability to enable faster decision-making, improve ROI, and enhance customer relationships through predictive analytics and intelligent automation. Digital Digest's new hub is poised to be an indispensable resource, offering the critical insights needed to capitalise on these opportunities.
To explore the new AI Digital Marketing Insights Hub and access its comprehensive resources, please visit digitaldigest.au
Media Contact
Organization: Digital Nomads HQ PTY LTD
Contact Person Name: Benjamin Paine
Website: https://digitalnomadshq.com.au/
Email: [email protected]
Contact Number: +1300633100
Address: 208/45 Brisbane Road
Address 2: Mooloolaba
City: Sunshine Coast
State: Queensland
Country: Australia
SOURCE: Digital Nomads HQ PTY LTD
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Blue Earth Summit highlights regenerative wool's climate potential
The discussion titled 'Circular by Nature – Rethinking Innovation in Natural Fibres' was held at the London Climate Action Week. It centred on the tangible benefits of wool, supported by evidence-based land management practices, innovative product development, and circular design principles. The panel, moderated by Amy Nguyen, featured participants including Clare Cannon, a Merino woolgrower from 'Woomargama Station' in Australia; Chris Gaffney, CEO of Johnsons of Elgin; Amy Powney, creative director and founder at AKYN; and Elisabeth van Delden, sustainability manager for Europe at Woolmark. The panellists emphasised the need for increased cooperation across the sector and promoted regenerative wool as a beneficial solution for the environment. Central to this conversation was the Woolmark+ roadmap, which outlines a strategy for incorporating wool into sustainable fashion models. This framework focuses on enhancing nature-positive production, establishing wool as a preferred circular fibre, and fostering prosperous rural communities. Australian woolgrower Clare Cannon provided insights into the positive ecological effects of regenerative grazing on her farm, including the resurgence of endangered bird species and native vegetation. 'Our expertise isn't theoretical; it's grounded in day-to-day realities. We have implemented practical strategies for preserving biodiversity, improving soil health, and reducing emissions as we journey towards nature positive. These are not buzzwords for us but part of our innate identity as stewards of the land,' Cannon stated. Gaffney discussed how continuous innovation is essential for maintaining the longevity of brands. 'You don't become a heritage brand without constantly innovating,' he said. van Delden highlighted current global carbon accounting methods prioritise carbon emissions and neglect factors such as water management, biodiversity and soil health. 'Woolmark+ helps bridge the gap between real on-farm outcomes and the growing demand from brands and investors for measurable impact. Whether it's decarbonisation, biodiversity uplift, or material circularity - the roadmap offers a science-led, scalable way to integrate wool into strategies focused on risk reduction, resilience, and long-term value creation,' she said. In November 2024, the Australian Government allocated A$4m ($2.6m) to support Woolmark's new Australian Wool Industry Insetting Programme, which is designed to lower emissions within the textile supply chain. "Blue Earth Summit highlights regenerative wool's climate potential" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Associated Press
an hour ago
- Associated Press
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP® companion diagnostic specific to stenoparib. The acceptance covers 40 claims and marks a key step in Allarity's global strategy to protect the potential international commercialization of its proprietary DRP® platform alongside the clinical development of stenoparib. The granted patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted within 20 working days thereafter. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'This latest patent acceptance from Australia represents another important achievement in our efforts to secure international IP protection for our DRP® technology. As we continue advancing stenoparib through Phase 2 trials toward U.S. regulatory approval, we are also building a robust intellectual property position in key global markets.' Allarity previously secured a European patent for the Stenoparib DRP® and holds 18 granted patents for drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP® remain pending in the U.S., Canada, Japan, China, and India. About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected grant and scope of the Australian patent for the Stenoparib DRP®; the anticipated contribution of this patent to the Company's global intellectual property strategy; and the Company's ability to advance and commercialize stenoparib in Australia and other key markets. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the potential for opposition to the patent grant; changes in regulatory timelines or requirements; failure to obtain regulatory approval for stenoparib or its companion diagnostic; and risks inherent in developing and commercializing biopharmaceutical products. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: [email protected] Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 [email protected] Attachment
Yahoo
3 hours ago
- Yahoo
Santos gives XRG Consortium six weeks for $18.7bn takeover review
Australia-based Santos has granted exclusive due diligence access for six weeks to the consortium led by Abu Dhabi National Oil Company (ADNOC), which offered $18.7bn for the Australian oil and gas producer. Santos entered a process and exclusivity deed with the XRG Consortium, led by ADNOC subsidiary XRG. The non-binding indicative proposal suggests an acquisition of all issued shares of Santos at a cash price of $5.76 (A$8.89) per share. The process deed outlines the terms under which the consortium will conduct due diligence and simultaneously negotiate a binding scheme implementation deed to finalise the acquisition. The consortium, which includes Abu Dhabi Development Holding Company and Carlyle, has been granted a six-week exclusive period to access Santos' due diligence data starting from today. During the exclusivity period, Santos is bound by standard non-disclosure obligations, including "no shop", "no talk", "no due diligence", and "notification" requirements. However, a fiduciary exception allows Santos' Board to entertain potentially superior offers from other interested parties, beginning four weeks from the date of the data room opening. The confidentiality terms agreed upon between Santos and the XRG consortium are detailed in a separate agreement, ensuring the protection of sensitive information throughout the purchase process. Santos has operations across Australia, Papua New Guinea, Timor-Leste and the US. The company's operating structure consists of three regional business units focused on implementing corporate strategy and a midstream energy solutions business unit. The company has a portfolio of liquefied natural gas plants adjacent to prolific gas resources and diverse integrated oil and gas production assets. "Santos gives XRG Consortium six weeks for $18.7bn takeover review" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
